Cytokinetics, Incorporated (NASDAQ:CYTK) Weekly Ratings on Jun 29, 2018

June 29, 2018 - By Cynthia Ashman

Cytokinetics, Incorporated (NASDAQ:CYTK) Corporate Logo
Big Money Sentiment decreased to 0.88 in 2018 Q1. It has change of 0.23, from 2017Q4’s 1.11. The ratio fall due to Cytokinetics, Incorporated positioning: 19 sold and 37 reduced. 19 funds acquired stakes and 30 increased stakes. Investors holded 38.16 million in 2017Q4 but now own 36.39 million shares or 4.65% less.
Prelude Cap Mgmt Ltd Liability holds 0.02% or 43,743 shs. 3.39M were reported by Vanguard Gp. Goldman Sachs Incorporated holds 354,263 shs or 0% of its capital. Mason Street Ltd Com has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 14,051 shs. American Gru has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Barclays Pcl holds 23,611 shs. Bnp Paribas Arbitrage Sa accumulated 14,586 shs. Tekla Capital Limited Liability Corp invested in 0.04% or 137,797 shs. Voya Investment Management Ltd Llc accumulated 19,190 shs or 0% of the stock. Nebraska-based Ameritas Investment Ptnrs has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Ls Advsr Limited Liability Co accumulated 1,487 shs or 0% of the stock. Swiss Comml Bank holds 74,100 shs or 0% of its capital. Hall Laurie J Trustee has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Drw Ltd Llc stated it has 14,000 shs or 0.01% of all its holdings. 68 are held by Parkside Fin Financial Bank And.

Cytokinetics, Incorporated had 5 sales and 0 insider purchases since January 16, 2018. This’s net activity of $147,942. McDowell Caryn Gordon sold 2,709 shs worth $24,381. The insider Malik Fady Ibraham sold 3,000 shs worth $26,850.

Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Coverage

In total 2 analysts cover Cytokinetics Inc (NASDAQ:CYTK). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CYTK) has 100% bullish analysts. 4 are the (NASDAQ:CYTK)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Friday, January 19 the firm has “Buy” rating by H.C. Wainwright given. On Wednesday, February 21 the stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Overweight” rating by Morgan Stanley. On Monday, June 18 the firm has “Buy” rating by H.C. Wainwright given. On Friday, April 27 H.C. Wainwright maintained Cytokinetics, Incorporated (NASDAQ:CYTK) rating. H.C. Wainwright has “Buy” rating and $2000 target. Listed here are Cytokinetics, Incorporated (NASDAQ:CYTK) PTs and latest ratings.

18/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0000 Maintain
21/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $17 New Target: $18 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0 Maintain

CYTK hit $8.3 during the last trading session after $0.1 change.Currently Cytokinetics, Incorporated is downtrending after 37.37% change in last June 29, 2017. CYTK has 89,205 shares volume. CYTK underperformed the S&P500 by 49.94%.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.The company has $449.84 million market cap. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.Last it reported negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

For more Cytokinetics, Incorporated (NASDAQ:CYTK) news released recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Benzinga.com or Benzinga.com. The titles are as follows: “Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to …” released on June 08, 2018, “Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher” on June 18, 2018, “Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide” with a publish date: June 18, 2018, “42 Stocks Moving In Monday’s Mid-Day Session” and the last “60 Biggest Movers From Yesterday” with publication date: June 19, 2018.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: